G1 Therapeutics, Inc. Common Stock
GTHX
GTHX was delisted on the 17th of September, 2024.
104 hedge funds and large institutions have $287M invested in G1 Therapeutics, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 42 increasing their positions, 18 reducing their positions, and 18 closing their positions.
193% more capital invested
Capital invested by funds: $98.2M → $287M (+$189M)
133% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 18
110% more call options, than puts
Call options by funds: $1.42M | Put options by funds: $676K
39% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 18
6% more funds holding
Funds holding: 98 → 104 (+6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$16.9M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
+$10.1M |
| 3 |
Fisher Asset Management
Camas,
Washington
|
+$7.16M |
| 4 |
Millennium Management
New York
|
+$5.08M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$3.95M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$17.4M |
| 2 |
CA
CHI Advisors
New York
|
-$5.06M |
| 3 |
Renaissance Technologies
New York
|
-$4.13M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$3.47M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$2.64M |
GTHX Hedge Fund Activity: Q3 2022 in Review
104 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in G1 Therapeutics, Inc. Common Stock (GTHX) for Q3 2022, worth a combined $287M — up 193% from $98.2M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new GTHX positions and 18 closed out — a net gain of 7 holders — while 42 added to existing stakes and 18 trimmed.
The largest buyer was State Street, adding an estimated $16.9M. The largest seller was Woodline Partners, cutting an estimated $17.4M.
- 104 institutional investors held G1 Therapeutics, Inc. Common Stock (GTHX) as of Q3 2022, up from 98 in Q2 2022.
- Funds reported $287M of G1 Therapeutics, Inc. Common Stock stock for Q3 2022, up 193% quarter-over-quarter.
- 25 funds opened new G1 Therapeutics, Inc. Common Stock positions in Q3 2022 and 18 closed out, a net change of +7 holders.
- The largest G1 Therapeutics, Inc. Common Stock buyer in Q3 2022 was State Street, an estimated $16.9M added.
- The largest G1 Therapeutics, Inc. Common Stock seller in Q3 2022 was Woodline Partners, an estimated $17.4M sold.
Based on aggregated 13F filings for Q3 2022.